Teva Pharmaceutical Industries Financial Statements (TEVA)
|
|
|
|
Report date
|
|
|
09.02.2022 |
10.02.2023 |
12.02.2024 |
05.02.2025 |
03.02.2026 |
|
29.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
15 878 |
14 925 |
15 845 |
16 544 |
17 257 |
|
17 348 |
|
Operating Income, bln rub |
|
|
1 716 |
-2 197 |
433.0 |
-303.0 |
2 157 |
|
2 289 |
|
EBITDA, bln rub |
? |
|
4 409 |
-925.0 |
1 558 |
4 431 |
3 141 |
|
3 270 |
|
Net profit, bln rub |
? |
|
417.0 |
-2 446 |
-559.0 |
-1 639 |
1 410 |
|
1 564 |
|
|
OCF, bln rub |
? |
|
798.0 |
1 590 |
1 368 |
1 247 |
1 649 |
|
1 714 |
|
CAPEX, bln rub |
? |
|
562.0 |
548.0 |
526.0 |
498.0 |
501.0 |
|
542.0 |
|
FCF, bln rub |
? |
|
236.0 |
1 042 |
842.0 |
749.0 |
1 148 |
|
1 172 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
5 878 |
9 170 |
7 212 |
8 366 |
6 780 |
|
6 742 |
|
Cost of production, bln rub |
|
|
8 284 |
7 952 |
8 200 |
8 481 |
8 320 |
|
8 317 |
|
R&D, bln rub |
|
|
1 094 |
838.0 |
953.0 |
1 055 |
1 013 |
|
989.0 |
|
Interest expenses, bln rub |
|
|
891.0 |
930.0 |
1 029 |
941.0 |
916.0 |
|
905.0 |
|
|
Assets, bln rub |
|
|
47 666 |
44 011 |
43 479 |
39 326 |
40 747 |
|
40 040 |
|
Net Assets, bln rub |
? |
|
10 278 |
7 804 |
7 506 |
5 373 |
7 910 |
|
8 228 |
|
Debt, bln rub |
|
|
23 459 |
21 561 |
20 153 |
18 079 |
17 382 |
|
16 907 |
|
Cash, bln rub |
|
|
2 165 |
2 801 |
3 226 |
3 300 |
3 556 |
|
3 741 |
|
Net debt, bln rub |
|
|
21 294 |
18 760 |
16 927 |
14 779 |
13 826 |
|
13 166 |
|
|
Ordinary share price, rub |
|
|
8.01 |
9.12 |
10.4 |
22.0 |
31.2 |
|
35.8 |
|
Number of ordinary shares, mln |
|
|
1 102 |
1 110 |
1 119 |
1 131 |
1 149 |
|
1 156 |
|
|
Market cap, bln rub |
|
|
8 827 |
10 123 |
11 682 |
24 927 |
35 860 |
|
41 344 |
|
EV, bln rub |
? |
|
30 121 |
28 883 |
28 609 |
39 706 |
49 686 |
|
54 510 |
|
Book value, bln rub |
|
|
-17 228 |
-16 099 |
-15 058 |
-14 192 |
-11 871 |
|
-11 203 |
|
|
EPS, rub |
? |
|
0.38 |
-2.20 |
-0.50 |
-1.45 |
1.23 |
|
1.35 |
|
FCF/share, rub |
|
|
0.21 |
0.94 |
0.75 |
0.66 |
1.00 |
|
1.01 |
|
BV/share, rub |
|
|
-15.6 |
-14.5 |
-13.5 |
-12.5 |
-10.3 |
|
-9.69 |
|
|
EBITDA margin, % |
? |
|
27.8% |
-6.20% |
9.83% |
26.8% |
18.2% |
|
18.8% |
|
Net margin, % |
? |
|
2.63% |
-16.4% |
-3.53% |
-9.91% |
8.17% |
|
9.02% |
|
FCF yield, % |
? |
|
2.67% |
10.3% |
7.21% |
3.00% |
3.20% |
|
2.83% |
|
ROE, % |
? |
|
4.06% |
-31.3% |
-7.45% |
-30.5% |
17.8% |
|
19.0% |
|
ROA, % |
? |
|
0.87% |
-5.56% |
-1.29% |
-4.17% |
3.46% |
|
3.91% |
|
|
P/E |
? |
|
21.2 |
-4.14 |
-20.9 |
-15.2 |
25.4 |
|
26.4 |
|
P/FCF |
|
|
37.4 |
9.72 |
13.9 |
33.3 |
31.2 |
|
35.3 |
|
P/S |
? |
|
0.56 |
0.68 |
0.74 |
1.51 |
2.08 |
|
2.38 |
|
P/BV |
? |
|
-0.51 |
-0.63 |
-0.78 |
-1.76 |
-3.02 |
|
-3.69 |
|
EV/EBITDA |
? |
|
6.83 |
-31.2 |
18.4 |
8.96 |
15.8 |
|
16.7 |
|
Debt/EBITDA |
|
|
4.83 |
-20.3 |
10.9 |
3.34 |
4.40 |
|
4.03 |
|
|
R&D/CAPEX, % |
|
|
194.7% |
152.9% |
181.2% |
211.8% |
202.2% |
|
182.5% |
|
|
CAPEX/Revenue, % |
|
|
3.54% |
3.67% |
3.32% |
3.01% |
2.90% |
|
3.12% |
|
| Teva Pharmaceutical Industries shareholders |
